Monday May 15, 2017
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Wells Fargo (WFC) and Procter & Gamble (PG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>
On A Jet Plane: Global Week Ahead discusses the main issues and economic reports on deck for release this week.
Retail Sector’s Disappointing Earnings Results takes stock of the sector’s sub-par quarterly results and what’s ahead for the space. This weekly report also provides the Q1 earnings season scorecard.
Apple shares are up +34.3% in the year-to-date period, handily outperforming the S&P 500 (up +7%) and the Zacks Technology sector (up +14.2%), with each of the last two earnings releases adding to the stock’s momentum. “Services” revenues, which includes the App store, Apple Music and Apple Pay grew +18%, with App store sales growing +40% year over year, in the March quarter. Also, the company announced an increase in the share repurchase authorization by $50 billion, taking total authorization to $300 million. Apple raised its quarterly dividend by 10.5%. Plus, the buzz surrounding iPhone 8, which is already labeled a super cycle, is expected to allay investors fear about iPhone sales trajectory. However, macroeconomic headwinds in some key regions like China and increasing competition remain concerns. (You can read the full research report on Apple here >>)
Wells Fargo shares continue to struggle, reflecting lingering issues pertaining to the customer accounts issue. The stock is down -3.4% in the year-to-date period, underperforming the Zacks Major Banks industry, which is up +1% in the same time period. Wells Fargo lacks investment banking and capital markets assets that were a big source of strength for many of its peers in the first quarter of the year. But the bigger issue for the bank has been the customer accounts issue. Troubles have intensified following the bank’s $190-million settlement last year to resolve regulators’ claims of illegally opening millions of illegal accounts. Recently, the Board of Directors released the findings of the independent investigation into the company’s retail banking sales practices which resulted in compensation actions, among the largest in corporate history. While the current crisis at the company will take some time to alleviate, the Zacks analyst thinks continued growth in loans and deposits, coupled with cost cuts (the bank plans $4 billion in cost cuts by 2019) should help support results. (You can read the full research report on Wells Fargo here >>)
Procter & Gamble outperformed the Zacks Consumer Staples sector in the past year (+5.5% vs. +2.9%). However, P&G shares have underperformed the S&P 500 index in the year-to-date period (up +2.5% vs. +7.1%). P&G’s fiscal third-quarter earnings beat expectations while revenues missed estimates. Organic sales growth declined in the last quarter reflecting weak market growth. The company has been struggling to boost market growth for the last few quarters. Also, significant negative forex impact has been hurting sales. But the Zacks analyst likes the fact that P&G is speeding up innovations and investments to counter softening industry growth. Its productivity improvements and aggressive cost-saving efforts are also consistently helping to boost profit levels. (You can read the full research report on Procter & Gamble here >>)
Other noteworthy reports we are featuring today include Celgene (NASDAQ:CELG), Goldman Sachs (GS) and General Motors (GM).
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
Today's Must Read
Featured Reports
Celgene (CELG) Tops Q1 Earnings, Sales Miss Due to Otezla
The Zacks analyst thinks Revlimid should continue to drive growth for Celgene as the company progresses on the label expansion efforts. The weakness in Otezla sales is temporary and should rebound.
Goldman (GS) Remains on Growth Track; Legal Risks Linger
The Zacks analyst thinks Goldman's Q1 results depict organic growth and strong capital position. Also, business diversification remains a key strength.
U.S. Bancorp (USB) Q1 Depicts Improving Revenue Trends
The Zacks analyst thinks U.S. Bancorp experienced impressive revenue growth in Q1 aided by increase in loans and deposits. However, mounting expenses and provisions remained undermining factors.
BlackRock (BLK) Witnesses Continued Revenue Growth in Q1
The covering analyst thinks BlackRock's initiatives to gain market share in the ETF business should continue to drive revenue growth.
Mondelez (MDLZ) Surpasses Q1 Earnings, Fx Headwinds Hurt
According to the covering analyst, though margins remain consistently strong backed by cost savings and productivity gains, currency headwinds raise concerns.
General Motors (GM) Beats on Q1 Earnings & Revenue, Up Y/Y
Product launches and technology development will benefit GM, but weak used car pricing and challenging pricing environment are concerns.
Kimberly-Clark (NYSE:KMB) Tops on Q1 Earnings on Favorable Currency Impact
The Zacks analyst thinks cost-containment efforts, improved operating profits and lower taxes favorably impacted the bottom line.
New Upgrades
Geron (GERN) Focused on Developing its Cancer Drug, Imetelstat
The Zacks analyst thinks agreement with J&J for imetelstat will provide it with a strong partner as well as funds. However, dependence on a single pipeline candidate raises concerns.
TransDigm (TDG) Q2 Earnings Beat, Acquisitions Drive Growth
The Zacks analyst thinks strong momentum in commercial aftermarket revenues continues to drive growth for TransDigm. Also, its strategic acquisitions will likely boost its core business going forward.
Molina Healthcare (MOH) Tops Q1 Earnings on Higher Revenues
The covering analyst views Molina's strong first quarter results favorably. A steady increase in top line, increasing membership, inorganic growth, strong balance sheet will drive long term growth.
New Downgrades
Mylan (NASDAQ:MYL) Tops Q1 Earnings, Sales Miss on EpiPen Decline
The Zacks analyst thinks sales of Mylan's EpiPen will continue to remain weak. The CRL for generic Advair and warning letter for its manufacturing facility will also remain a hangover on shares.
Andersons (ANDE) Q1 Earnings in Line, Near-Term Woes Stay
The covering analyst thinks Andersons' results will be hit by oversupply, planting delays and increases in interest rates. Further, vomitoxin issues continue to impact Ethanol Group's performance.
Gibraltar Industries' (ROCK) Future Prospects Bleak
Gibraltar is exposed to risks from poor conditions in the commodity & energy related markets, forex woes and industry rivalry.
Wells Fargo & Company (NYSE:WFC): Free Stock Analysis Report
Procter & Gamble Company (The) (NYSE:PG): Free Stock Analysis Report
Goldman Sachs Group, Inc. (The) (NYSE:GS): Free Stock Analysis Report
General Motors Company (NYSE:GM): Free Stock Analysis Report
Apple Inc. (NASDAQ:AAPL): Free Stock Analysis Report
Original post
Zacks Investment Research